We found that CDKN2A LOF tumors had significantly lower DCR and were twice as likely to exhibit disease progression when compared to CDKN2A wild-type tumors (PD as best response in 46% vs. 21%, Chi-squared p = 0.021, Fig. 4 and Supplemental Fig. 3); this result was most pronounced in those treated with ICB for metastatic disease (48% vs. 23%, Chi-squared p = 0.033). This evidence concerns the gene CDKN2A and metastatic neoplasm.